

**IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE**

ANDRULIS PHARMACEUTICALS CORP.,	)	
	)	
Plaintiff,	)	
	)	Civil Action No. 13-1644 (RGA)
v.	)	
	)	
CELGENE CORP.,	)	
	)	
Defendant.	)	

NOTICE OF APPEAL

Notice is hereby given that Andrulis Pharmaceuticals Corporation, in the above named case, hereby appeals in accordance with 28 U.S.C. §§ 1292 and 1295 to the United States Court of Appeals for the Federal Circuit from the final judgment dated and entered in this action on July 28, 2015 (D.I. 156), including the district court’s Memorandum Opinion (D.I. 149) finding claim 2 of U.S. Patent No. 6,140,346 invalid as indefinite under 35 U.S.C. § 112(b), (formerly 35 U.S.C. § 112, ¶ 2), the Court’s constructions of claim 2 terms “administering,” “enhanced,” “enhanced combination,” “enhanced therapeutically-effective amounts of thalidomide,” and “said neoplastic diseases are sensitive to said enhanced combination” (D.I. 149), and appeals all orders, judgments, and rulings entered in this action upon which the invalidity ruling is based.

Dated: August 27, 2015

/s/ Kenneth L. Dorsney
Kenneth L. Dorsney (#3726)
MORRIS JAMES LLP
500 Delaware Avenue, Suite 1500
Wilmington, Delaware 19801
(302) 888-6800
kdorsney@morrisjames.com

*Attorney for Plaintiff
Andrulis Pharmaceuticals Corp.*

OF COUNSEL:

Paul J. Skiermont (*pro hac vice*)
Alexander E. Gasser (*pro hac vice*)
Parvathi Kota (*pro hac vice*)
Sarah. E. Simmons (*pro hac vice*)
Shellie R. Stephens (*pro hac vice*)
Steven J. Udick (*pro hac vice*)
Eliot J. Walker (*pro hac vice*)
SKIERMONT PUCKETT LLP
2200 Ross Avenue, Suite 4800W
Dallas, Texas 75201
(214) 978-6600 (telephone)
paul.skiermont@skiermontpuckett.com
alex.gasser@skiermontpuckett.com
parvathi.kota@skiermontpuckett.com
sarah.simmons@skiermontpuckett.com
shellie.stephens@skiermontpuckett.com
steve.udick@skiermontpuckett.com
eliot.walker@skiermontpuckett.com